文献速递乳腺乳腺X线MRDSA

起源于主要输乳管的乳腺癌影像生物标志物:乳腺导管腺癌(DAB)

Imaging biomarkers of breast cancers originating from the major lactiferous ducts: Ductal adenocarcinoma of the breast, DAB.
PubMed 文献 · Eur J Radiol · 2022-06-04

本文描述乳腺导管腺癌(DAB)的六种乳腺X线影像生物标志物,并将影像表现与大范围组织病理学对应,其中四种亚型有特征性恶性钙化,一种表现为乳头溢液且乳腺X线常隐匿但乳管造影和MRI可检出,一种表现为结构扭曲;MRI对判断病变范围和指导手术起关键作用。作者认为DAB实为浸润性癌,需重新评估其诊断和管理标准。

要点

  • DAB有六种乳腺X线影像生物标志物,四种亚型伴特征性恶性钙化。
  • 腔内坏死型钙化为碎裂或点状铸型钙化,腔内液体型钙化呈跳跃石样或珍珠串样。
  • 血性或浆液性乳头溢液亚型乳腺X线常隐匿,乳管造影和MRI可检出。

核心结论

  • 放射科医生可利用这些明确的影像生物标志物识别乳腺导管腺癌(DAB);MRI在判断病变范围和指导手术管理中起关键作用;不断积累的证据表明该亚型实为浸润性癌,亟需重新评估这一认识不足的恶性肿瘤的诊断和管理标准。

研究设计与样本

  • 将乳腺影像生物标志物与大范围技术对应的组织病理学所见进行对照,并补充亚大体厚切片组织病理学证据以展示新生导管样结构(新导管)的复杂三维结构。

关键影像表现/征象

  • 四个DAB亚组在乳腺X线上有特征性恶性型钙化。
  • 其中两个亚组以腔内坏死为特征,乳腺X线上产生碎裂或点状铸型钙化。
  • 另两个亚组以导管内液体产生为特征,液体最终可能钙化,产生跳跃石样或珍珠串样钙化。
  • 第五个DAB亚组表现为血性或浆液性乳头溢液,乳腺X线通常隐匿,但乳管造影和MRI可检出。
  • 第六个亚组表现为乳腺X线上不伴钙化的结构扭曲。

诊断标准与关键数值

  • DAB共有六种影像生物标志物(乳腺X线肿瘤特征)。
  • 碎裂或点状铸型钙化对应腔内坏死亚组。
  • 跳跃石样或珍珠串样钙化对应导管内液体产生并钙化的亚组。
  • 血性或浆液性乳头溢液亚组乳腺X线通常隐匿,乳管造影和MRI可检出。
  • 结构扭曲且无相关钙化对应第六亚组。

临床应用与阅片要点

  • 放射科医生可利用上述明确的影像生物标志物识别DAB。
  • MRI在判断疾病范围和指导手术管理中起关键作用。
  • 由于错误地假定DAB为非浸润性,免疫化学生物标志物通常不从DAB本身检测。
  • 作者认为该亚型实为浸润性癌,亟需重新评估其诊断和管理标准。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

PURPOSE: As we have previously demonstrated, breast cancers originating in the major lactiferous ducts and propagating through the process of neoductgenesis are a distinct subtype of invasive breast cancers, although by current practice they are placed within the group termed ductal carcinoma in situ (DCIS) and are consequently underdiagnosed and undertreated. Imaging biomarkers provide a reliable indication of the site of origin of this breast cancer subtype (Ductal Adenocarcinoma of the breast, DAB) and have excellent concordance with long-term patient outcome. In the present paper, the imaging biomarkers of DAB are described in detail to encourage and facilitate its recognition as a distinct, invasive breast cancer subtype.

METHODS: Correlation of breast imaging biomarkers with the corresponding histopathological findings using large format technology, with additional evidence from subgross, thick section histopathology to demonstrate the complex three-dimensional structure of the newly formed duct-like structures, neoducts.

RESULTS: There are six imaging biomarkers (mammographic tumour features) of DAB. Four subgroups have characteristic malignant-type calcifications on the mammogram. Two of these are characterized by intraluminal necrosis producing fragmented or dotted casting type calcifications on the mammogram; another two subgroups are characterized by intraductal fluid production which may eventually calcify, producing skipping stone-like or string of pearl-like calcifications. A fifth DAB subgroup presents with bloody or serous nipple discharge and is usually occult on mammography but is detectable with galactography and magnetic resonance imaging (MRI). The sixth subgroup presents as architectural distortion on the mammogram without associated calcifications.

CONCLUSIONS: Radiologists can use these well-defined imaging biomarkers to readily detect Ductal Adenocarcinoma of the Breast, DAB. Immunochemical biomarkers are generally not determined from the DAB itself, due to the erroneous assumption that DAB is non-invasive. MRI plays a crucial role in determining disease extent and guiding surgical management. The accumulating evidence that this disease subtype is, in fact, an invasive cancer, necessitates an urgent re-evaluation of the diagnostic and management criteria for this poorly understood malignancy.

来源:Eur J Radiol,查看原文。版权归原作者所有。

引用

  1. Tabár, Dean, Lee Tucker, et al. Imaging biomarkers of breast cancers originating from the major lactiferous ducts: Ductal adenocarcinoma of the breast, DAB. Eur J Radiol. 2022. PMID: 35751940. doi:10.1016/j.ejrad.2022.110394

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。